AKT1 and neoplasm: Two independent groups reported that compared to conventionally grown CD19 CAR T cells, the addition of AKT inhibitors during manufacture resulted in enrichment of CAR T cells with a CD62L-expressing central memory (TCM) phenotype and enhanced anti-tumor efficacy in different xenograft models, without compromising cell yields (62, 63).